James R Howard-tripp
Chairman and CEO
Management
GeneNews
Canada
Biography
Mr. Howard-Tripp, who joined the GeneNews Board in 2002, has specialized in the research, development and launch of innovative pharmaceutical products and the growth and development of the companies that research and market them. He has been involved in the management (GD Searle, Wyeth-Ayerst) and creation (Allelix, Labopharm, Dermacor) of several successful companies. He has 13 years' experience as a President and CEO and has sat on multiple Boards, most as Chairman. Most recently, as President and CEO of Labopharm, he oversaw the research, development and approval of 3 products and the launch of 2, with the lead product marketed in 19 countries (total end user sales approximately $100 million). During his tenure, Labopharm raised >$250 million in the public markets (US IPO $112 million in 2006) and achieved >$100 million in deal revenue (partners included: Sanofi-Aventis, Purdue Pharma, Merck Inc., Grunenthal, Angelini and Esteve). Additionally, he has served on various scientific and industry committees as well as several not-for-profit boards.
Research Interest
research, development and launch of innovative pharmaceutical products
